| Genzyme Belgium | Genzyme Corporate | Search | Contact us | |||||||||
![]() |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
Reconstitution and administration of Aldurazyme® Please see the full prescribing information in Dutch or in French (PDF) for Aldurazyme®. The recommended dosage regimen of Aldurazyme® (laronidase) is 100 U/kg of body weight administered once weekly as an intravenous infusion. Pretreatment with antipyretics and/or antihistamines is recommended 60 minutes prior to the start of the first few infusions, upon re-administration following interruption of treatment, and if otherwise clinically indicated.[1] The total volume of the infusion is determined by the patient’s body weight and should be delivered over approximately three to four hours. Patients with a body weight of 20 kg or less should receive a total volume of 100 ml. Patients with a body weight of greater than 20 kg should receive a total volume of 250 ml. The initial infusion rate of 2 U/kg/hr may be incrementally increased every 15 minutes during the first 1-1.5 hours, as tolerated, until a maximum infusion rate of 43U/kg/hr is reached. The maximum rate is then maintained for the remainder of the infusion (2-3 hours). [1]
For Patients weighing 20 kg or less than 20 kg: [1]
For Patients weighing more than 20 kg: [1]
References: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Terms and Conditions of Use | Privacy Policy | © 2012 Genzyme Corporation, a Sanofi Company. All rights reserved. | ||